In this article
Semaglutide and tirzepatide are different medicines. They are often discussed together in online weight-loss advertising, but choosing between them requires more than comparing a headline weight-loss percentage.
The product name, route, indication, dosing instructions, health history, and affordability all matter. So does whether the proposed medicine is an approved product or a compounded preparation. This guide prepares you for that conversation; it does not choose a medication for you.
Compare the exact products with a clinician. Semaglutide and tirzepatide differ, and research on an approved formulation is not evidence that every compounded version or route performs the same way.
What to know first
- Both medication families require an individualized assessment.
- The same active-ingredient name can appear in products with different formulations and indications.
- The best financial comparison includes the long-term care and medication cost.
The medication is only one part of the name
Semaglutide is associated with approved products including Wegovy and Ozempic; tirzepatide with products including Zepbound and Mounjaro. Indications and formulations differ. Read the actual label and treatment proposal rather than using the brand names interchangeably.
A compounded prescription is a separate preparation. Its name may include one of these ingredients, but that does not make it the approved branded product or establish equivalence.
Why trial percentages need context
Trials study particular products, doses, populations, and follow-up periods. A percentage in an advertisement is incomplete without those details. A trial in people without diabetes, for example, does not necessarily predict the same response for a person with a different medical history.
The results of approved-drug trials should not be transferred automatically to a compounded product with another concentration, route, or additive. Ask the clinician what evidence supports the exact proposal and what outcomes are realistic for you.
The clinical conversation should include more than weight
Discuss your current medicines, prior treatment response, side effects, digestive conditions, and relevant personal or family history. Ask what monitoring and follow-up are needed and how the treatment fits management of any other conditions.
If you have diabetes or use medicines that lower blood glucose, the care plan needs to account for that. Do not combine, substitute, or switch these treatments using a review-site comparison.
How to compare cost fairly
Obtain a quote for the exact medication and the dose prescribed—not a starter dose you may no longer use. Add membership, consultation, testing, and delivery charges. Then check whether the plan is billed every four weeks, monthly, or as a prepaid term.
Our GLP-1 price comparison guide helps with this. The best tirzepatide provider comparison also distinguishes compounded and approved-product pathways.
If you are considering a switch
Ask the current and prospective prescribers for a coordinated plan. Provide the exact current product, last prescribed regimen, tolerance, and pharmacy label. A milligram amount or syringe marking from one medication is not a conversion instruction for the other.
A billing decision is not a medical transition plan. If a provider change is driven by cost, make sure follow-up and access continue rather than trying to improvise with medication left from an earlier order.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- MedlinePlus: semaglutide injectionMedical reference · Checked September 21, 2026
- MedlinePlus: tirzepatide injectionMedical reference · Checked September 21, 2026
- NIDDK: prescription medications for weight managementMedical reference · Checked September 21, 2026
- FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 21, 2026
- FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction